The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
STM-01: Phase I EFFTox study of aurora A kinase inhibitor alisertib (MLN8237) given in combination with selective VEGFR inhibitor pazopanib for therapy of solid tumors.
 
Arkadiusz Z. Dudek
Stock and Other Ownership Interests - Vanquish Oncology
Consulting or Advisory Role - Vanquish Oncology
 
Imran Unal
No Relationships to Disclose
 
Hui Xie
No Relationships to Disclose
 
Lawrence Eric Feldman
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - Celgene
Research Funding - Bristol-Myers Squibb (Inst); Soligenix (Inst)
 
Neeta K. Venepalli
No Relationships to Disclose
 
Oana Cristina Danciu
No Relationships to Disclose